Y-90 Versus SBRT for Inoperable HCC

Summary

This phase II trial tests whether Y-90 segmentectomy (internal radiation) versus stereotactic body radiation therapy (external radiation) is more optimal in treating inoperable liver cancer. Y-90 segmentectomy consists into very tiny radioactive glass beads that can be injected into the liver through the blood vessels supplying the liver. Stereotactic body radiation therapy uses special equipment to position a patient and deliver external radiation to tumors with high precision. This study many help doctors determine which treatment, Y-90 segmentectomy or SBRT, works better in treating liver cancer.

Conditions

• Hepatocellular Carcinoma
• Stage I Hepatocellular Carcinoma AJCC v8
• Stage IA Hepatocellular Carcinoma AJCC v8
• Stage IB Hepatocellular Carcinoma AJCC v8
• Stage II Hepatocellular Carcinoma AJCC v8
• Stage III Hepatocellular Carcinoma AJCC v8
• Stage IIIA Hepatocellular Carcinoma AJCC v8
• Stage IIIB Hepatocellular Carcinoma AJCC v8
• Stage IVA Hepatocellular Carcinoma AJCC v8

Interventions

OTHER

Quality of Life

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

PROCEDURE

Yttrium-90 Microsphere Radioembolization

Given via injection

Sponsors & Collaborators

• American Society of Clinical Oncology

  collaborator OTHER

• Medical Research Foundation, Oregon

  collaborator OTHER

• Oregon Health and Science University

  collaborator OTHER

• Radiation Oncology Institute

  collaborator UNKNOWN

• Radiological Society of North America

  collaborator OTHER

• OHSU Knight Cancer Institute

  lead OTHER

Principal Investigators

• Nima Nabavizadeh · OHSU Knight Cancer Institute

Study Design

Allocation

RANDOMIZED

Purpose

DEVICE_FEASIBILITY

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-12-01

Primary Completion

2026-01-05

Completion

2026-01-05

FDA Device

Yes